Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma [ID6477]

  • In development
  • GID-TA11599
  • Expected publication date: 

28856-Pembrolizumab-for-Head-and-Neck-Squamous-Cell-Carcinoma-V1.0-MAY2024-NON-CONF.pdf (nihr.ac.uk)